

**Government of India**  
**Ministry of Chemicals and Fertilizers**  
**Department of Pharmaceuticals**

**Press Note**

Shastri Bhawan, New Delhi

Dated: 9<sup>th</sup> December, 2021

**Subject: - Approvals accorded under Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country.**

The Indian pharmaceutical industry is the 3<sup>rd</sup> largest in the world by volume. It has high market presence in several advanced economies such as the US and EU. The industry is well known for its production of affordable medicines, particularly in the generics space. However, the country is significantly dependent on the import of basic raw materials, viz., Bulk Drugs that are used to produce medicines. In some specific bulk drugs, the import dependence is 80 to 100%.

2. With an objective to attain self-reliance and reduce import dependence in these critical Bulk Drugs - Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country, the Department of Pharmaceuticals had launched a Production Linked Incentive (PLI) Scheme for promotion of their domestic manufacturing by setting up greenfield plants with minimum domestic value addition in four different Target Segments (In Two Fermentation based - at least 90% and in the Two Chemical Synthesis based - at least 70% ) for 41 products with a total outlay of Rs. 6,940 cr. for the period 2020-21 to 2029-30.

3. In total, 215 applications were received for the 36 products spread across the 4 Target Segments. Out of which, total 42 applications were approved by the Government with a total Committed Investment of Rs. 4,347.26 Crore and expected Employment Generation of around 8,792 persons.

4. Since few slots remained unfilled for certain products, applications were invited again with the last date of submission as 31.08.2021. Total 24 applications were received.

5. In the 9<sup>th</sup> Meeting of the Empowered Committee held on 25.11.2021, after considering all the applications received, the applications of following companies, which fulfill the prescribed criteria laid down in scheme guidelines have been approved, as under:

S.No.	Name of approved Applicant	Name of Eligible Product	Committed Production Capacity(in MT)	Committed Investment (in Rs. crores)
<b>Target Segment III - Key Chemical Synthesis Based KSMs/Drug Intermediates</b>				
1	M/s Alkimia Pharma-Chem Pvt. Ltd. (APCPL)	1,1 Cyclohexane Diacetic Acid (CDA)'	1500	22.47
<b>Target Segment IV - Other Chemical Synthesis Based KSMs/Drug Intermediates/APIs</b>				
1	M/s Globela Industries Pvt. Ltd. (GIPL)	Ofloxacin	100	22.00
2	M/s Globela Industries Pvt. Limited (GIPL)	Norfloxacin	60	15.51
3	M/s Alta Laboratories Limited (ALL)	Aspirin	2250	12.44
4	M/s Aviran Pharmachem Private Limited (APPL)	Artesunate	20	5.69
5	M/s K P Manish Global Ingredients Pvt. Ltd. (KPMGIPL)		80	15.00
6	M/s Sudarshan Pharma Industries Ltd. (SPIL)	Vitamin B6'	35	27.00
7	M/s Honour Lab Ltd. (HLL)		140	31.00

6. The setting up of these 8 plants will lead to total committed investment of about Rs.151.12 crore by the companies and employment generation of about 1,951. The commercial production of these plants is projected to commence from 1<sup>st</sup> April, 2023 onwards.

7. With this, the total applications approved under both rounds aggregate to 50 applicants with committed investment of Rs 4,498.38 crore and employment generation of about 10,743. Setting up of these plants will make the country self-reliant to a large extent in respect of these Bulk drugs.

\*\*\*